Join LB Pharmaceuticals for an in-person and virtual R&D Day featuring Roger S. McIntyre, MD, FRCPC (University of Toronto), alongside Heather Turner (CEO), Susan G. Kozauer (CMO), Kaya Pai Panandiker (CCO), Gad Soffer (COBO), and Joe Miller (CFO), as the Company looks ahead to its upcoming topline data readout in schizophrenia.

LB-102 is a novel, once-daily oral selective antagonist of D2, D3 and 5HT7 receptors with a unique bimodal mechanism. It is being developed by LB Pharma for the treatment of schizophrenia, bipolar depression, the adjunctive treatment of major depressive disorder, as well as other neuropsychiatric disorders, and has the potential to be the first therapy with this unique mechanism approved for neuropsychiatric disorders in the United States.

Topics will include:

• New scientific insights on LB-102’s unique mechanism of action that underlies the emerging clinical profile and opportunity across a wide variety of brain disorders
• Discussion of the Phase 3 trial program in schizophrenia, its upcoming topline data readout in the first half of 2027, and ongoing pre-commercial planning activities

A live question and answer session will follow the formal presentations.